Superworth

Emergent BioSolutions price to free cash flow EBS

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026
3.7×
10-year median
17.0×
Against its 10-year history
15th
percentile: 0 is its lowest day, 100 its highest
10-year range
2.6× to 486×
Peer median
9.4×

Emergent BioSolutions' price to free cash flow is 3.7× as of Oct 23, 2026.

That is below its ten-year median of 17.0×, lower than on 85% of days in the last ten years.

Over that time it ranged from 2.6× in Sep 2025 to 486× in Jan 2026.

The median for 10 large drugmakers of a similar size is 9.4×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far3.7×2.6×486×
2025466×2.6×468×
20243.2×3.0×15.1×
202310.8×10.3×12.9×
20229.3×7.3×123×
2021102×8.4×107×
202017.5×16.1×114×
201934.7×13.4×37.8×
201813.4×12.8×36.8×
201733.4×27.1×35.7×
201612.9×12.2×33.7×
201535.8×13.2×50.9×
201422.4×15.2×71.6×
20139.4×9.4×10.2×
20129.6×8.5×56.2×

Against its peers

Companies in Drug Manufacturers - General nearest Emergent BioSolutions' size, closest first, today.

CompanyPrice to free cash flow
EBSEmergent BioSolutions3.7×
NATRNatures Sunshine Products11.8×
ARVNArvinasn/m
PBYIPuma Biotechnology13.8×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics17.9×
CRMDCorMedix2.4×
COLLCollegium Pharmaceutical2.3×
ABUSArbutus Biopharman/m
AMPHAmphastar Pharmaceuticals7.0×
OMEROmerosn/m
Peer median9.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Emergent BioSolutions

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.